USE OF RANOLAZINE IN COMBINATION WITH AT LEAST ONE REMODELING AGENT FOR REVERSING LEFT VENTRICULAR REMODELING IN THE TREATMENT OF HEART FAILURE

摘要

The present invention relates to a method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.